Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

106 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rationale, design, and baseline characteristics of a study to evaluate the effect of febuxostat in preventing cerebral, cardiovascular, and renal events in patients with hyperuricemia.
Kojima S, Matsui K, Ogawa H, Jinnouchi H, Hiramitsu S, Hayashi T, Yokota N, Kawai N, Tokutake E, Uchiyama K, Sugawara M, Kakuda H, Wakasa Y, Mori H, Hisatome I, Waki M, Ohya Y, Kimura K, Saito Y; Febuxostat for Cerebral and Cardiorenovascular Events Prevention Study (FREED) investigators. Kojima S, et al. Among authors: kakuda h. J Cardiol. 2017 Jan;69(1):169-175. doi: 10.1016/j.jjcc.2016.02.015. Epub 2016 Apr 20. J Cardiol. 2017. PMID: 27005768 Free article. Clinical Trial.
Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy.
Kojima S, Matsui K, Hiramitsu S, Hisatome I, Waki M, Uchiyama K, Yokota N, Tokutake E, Wakasa Y, Jinnouchi H, Kakuda H, Hayashi T, Kawai N, Mori H, Sugawara M, Ohya Y, Kimura K, Saito Y, Ogawa H. Kojima S, et al. Among authors: kakuda h. Eur Heart J. 2019 Jun 7;40(22):1778-1786. doi: 10.1093/eurheartj/ehz119. Eur Heart J. 2019. PMID: 30844048 Free PMC article. Clinical Trial.
Optimal uric acid levels by febuxostat treatment and cerebral, cardiorenovascular risks: post hoc analysis of a randomized controlled trial.
Kojima S, Uchiyama K, Yokota N, Tokutake E, Wakasa Y, Hiramitsu S, Waki M, Jinnouchi H, Kakuda H, Hayashi T, Kawai N, Sugawara M, Mori H, Tsujita K, Matsui K, Hisatome I, Ohya Y, Kimura K, Saito Y, Ogawa H; Febuxostat for Cerebral and Cardiorenovascular Events Prevention Study (FREED) investigators. Kojima S, et al. Among authors: kakuda h. Rheumatology (Oxford). 2022 May 30;61(6):2346-2359. doi: 10.1093/rheumatology/keab739. Rheumatology (Oxford). 2022. PMID: 34605897 Clinical Trial.
Effect of febuxostat on clinical outcomes in patients with hyperuricemia and cardiovascular disease.
Konishi M, Kojima S, Uchiyama K, Yokota N, Tokutake E, Wakasa Y, Hiramitsu S, Waki M, Jinnouchi H, Kakuda H, Hayashi T, Kawai N, Sugawara M, Mori H, Tsujita K, Matsui K, Hisatome I, Ohya Y, Kimura K, Saito Y, Ogawa H; Febuxostat for Cerebral and Cardiorenovascular Events Prevention Study (FREED) investigators. Konishi M, et al. Among authors: kakuda h. Int J Cardiol. 2022 Feb 15;349:127-133. doi: 10.1016/j.ijcard.2021.11.076. Epub 2021 Dec 3. Int J Cardiol. 2022. PMID: 34864084 Clinical Trial.
C-reactive Protein Levels and Cardiovascular Outcomes After Febuxostat Treatment in Patients with Asymptomatic Hyperuricemia: Post-hoc Analysis of a Randomized Controlled Study.
Kojima S, Uchiyama K, Yokota N, Tokutake E, Wakasa Y, Hiramitsu S, Waki M, Jinnouchi H, Kakuda H, Hayashi T, Kawai N, Sugawara M, Mori H, Tsujita K, Matsui K, Hisatome I, Ohya Y, Kimura K, Saito Y, Ogawa H; Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy (FREED) investigators. Kojima S, et al. Among authors: kakuda h. Cardiovasc Drugs Ther. 2023 Oct;37(5):965-974. doi: 10.1007/s10557-022-07347-7. Epub 2022 Jun 1. Cardiovasc Drugs Ther. 2023. PMID: 35648242 Clinical Trial.
Effects of febuxostat on serum urate level in Japanese hyperuricemia patients.
Yamamoto T, Hidaka Y, Inaba M, Ishimura E, Ooyama H, Kakuda H, Moriwaki Y, Higami K, Ohtawara A, Hosoya T, Nishikawa H, Taniguchi A, Ueda T, Yamauchi T, Fujimori S, Mineo I, Yamanaka H. Yamamoto T, et al. Among authors: kakuda h. Mod Rheumatol. 2015 Sep;25(5):779-83. doi: 10.3109/14397595.2015.1016257. Epub 2015 Jun 12. Mod Rheumatol. 2015. PMID: 25671406 Clinical Trial.
A Retrospective Study of Pediatric Patients With Low- or Intermediate-Risk Acute Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation for the AML-05 Study Conducted by the Japanese Pediatric Leukemia/Lymphoma Study Group.
Hashii Y, Kawaguchi K, Kurakami H, Umeda K, Hasegawa D, Taki T, Hyakuna N, Ishida H, Takahashi Y, Nagasawa M, Yabe H, Yano M, Nakazawa Y, Fujisaki H, Matsumoto K, Yanagimachi M, Yoshida N, Kakuda H, Satou A, Tabuchi K, Tomizawa D, Taga T, Adachi S, Koh K, Kato K. Hashii Y, et al. Among authors: kakuda h. Transplant Cell Ther. 2024 Nov;30(11):1102.e1-1102.e12. doi: 10.1016/j.jtct.2024.08.011. Epub 2024 Aug 22. Transplant Cell Ther. 2024. PMID: 39181536
106 results